Eevia Health will issue new shares in a preferential rights issue of 21.6 MSEK
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on a rights issue with preferential rights for Eevia's existing shareholders ("Rights Issue"). The target amount is approximately SEK 21.6 million. The proceeds shall primarily finance sales and marketing efforts and increase working capital. About 82 percent of the Rights Issue is covered by subscription and guarantee commitments.
THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS NOT INTENDED TO BE PUBLISHED, DISCLOSED, OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, CANADA, SINGAPORE, OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
"Eevia Health has during the first half of 2022 significantly improved productivity and yield. We have a renewed and forward-leaning competitive stance in the markets with a clear aim to expand our business and make our operations profitable. Following major CAPEX investments in 2020-2021, Eevia now has a state-of-the-art facility with capacity to serve multiple new customers. This funding round enables us to work with new customers, provide sharper product positioning, and handle increased working capital demands from large potential orders. I am very impressed and grateful to our owners in Sweden, Norway, and Finland, who are still trusting and supporting Eevia despite tumultuous financial markets. Many of the largest owners have already underwritten subscription commitments for this equity issue. The Management Team is keenly committed to reciprocating this trust." says Stein Ulve, CEO at Eevia.
Key points for the equity issue
- Upon full subscription of the Rights Issue, Eevia will receive approximately SEK 21.6 million before issue costs.
- The Rights Issue is covered by approximately 43 percent subscription commitments and approximately 39 percent guarantee commitments, out of which 8 percentage points represents a top guarantee. In total, the Rights Issue is secured at a minimum of 82 percent.
- All existing shareholders receive one (1) subscription right for each (1) share held on the record date on October 27, 2022, and ten (10) subscription rights entitle the shareholder to a subscription of nine (9) new shares. The subscription price is SEK 1.50 per share and EUR 0.133 for shareholders through Euroclear Finland.
- The subscription period for the Rights Issue will run from November 1, 2022, to November 15, 2022. Trading in Subscription rights will commence on November 1 and end on November 10 on Spotlight Stock Market. Subscription rights that are not used or sold during this period become invalid and lose their value.
- Complete terms and instructions for the Rights Issue, as well as other information about the Company, will appear in the Information Memorandum, which is expected to be published around October 28, 2022.
- The Finnish shareholders need to transfer their shares to the book-entry system maintained by Euroclear Sweden before the record date of the Rights Issue in order to be able to trade on the subscription rights and the BTAs (paid subscribed shares) on Spotlight Stock Market Sweden.
USE OF PROCEEDS
Upon full subscription of the Rights Issue, Eevia will receive approximately SEK 21.6 million before issue costs for a total of approximately SEK 3 million (of which, the costs for the underwriting commitments amount to SEK 1 million). Use of the net proceeds from the Rights Issue is primarily planned to be used to increase the Company's net working capital. This will provide for the ability to undertake an increase in raw material inventory for bilberries and other materials, which may be needed to serve some large prospects in the pipeline. Improved net working capital will also enable the Company to handle growth in customer receivables.
A sum of SEK 6 million plus interest will be used to repay a credit line the Company opened in June 2022. The equity will also have a positive effect on Eevia's ability to attract credit financing for long-term growth. Eevia also needs to increase focus on developing the sales organization to facilitate continued growth. This will involve building a stronger marketing, regulatory, product management, and sales management team.
The Rights Issue
Based on authorization granted by the Extraordinary General Meeting on October 11, 2022, the Board of Directors in Eevia has, on October 20, 2022, resolved to conduct a Rights Issue that consists of a maximum of 14 376 015 newly issued shares. Upon full subscription in the Rights Issue, the Company will receive approximately SEK 21.6 million before issue costs.
All registered shareholders on the record date of October 27, 2022, have preferential rights to subscribe for shares in relation to their existing shareholdings, whereby each existing share entitles to one (1) subscription right and ten (10) subscription rights provide the right to subscribe for nine (9) new shares. The subscription price is SEK 1.50 per share and EUR 0.133 per share.
Subscription of shares shall also be possible without the subscription rights. If not all shares are subscribed with the subscription rights, the Board shall, within the framework of the Rights Issue's maximum amount, decide on the allocation of shares according to the following principles. The allotment shall be made firstly to those who have subscribed for shares by exercise of subscription rights, regardless of whether they were shareholders on the record date or not, and in the event of oversubscription, in relation to the number of subscription rights that each has exercised for subscription of shares, and to the extent that this is not possible, by drawing of lots; Secondly, to those who have applied for the subscription of shares without the exercise of subscription rights, and to the extent that this is not possible, by drawing of lots; Thirdly and lastly, any remaining shares shall be allocated to those who have provided guarantee commitments to subscribe for shares, pro-rata on the basis of their guarantee undertaking and, to the extent that this cannot be done, through drawing of lots.
The subscription period runs from November 1, 2022, until November 15, 2022. Subscription rights that are not exercised during the subscription period become invalid and lose their value. Trading of subscription rights is expected to take place on the Spotlight Stock Market during the period November 1-10, 2022. Trading in BTA's (paid subscribed shares) is expected to take place from November 1, 2022, until the shares subscribed in the Rights Issue are registered with the Finnish Trade Register.
The dilutive effect for the shareholders who choose not to participate in the Rights Issue amounts to approximately 47 percent of the shares and votes (calculated by dividing the number of new shares as a result of the Rights Issue by the total number of shares in the Company after a fully subscribed Rights Issue).
The Finnish shareholders need to transfer their shares to the book-entry system maintained by Euroclear Sweden before the record date of the Rights Issue in order to be able to trade on the subscription rights and the BTA (paid subscribed shares) on Spotlight Stock Market Sweden.
Subscription undertakings and guarantee commitments
The Rights Issue is covered to approximately 43 percent by subscription undertakings and to approximately 39 percent by guaranteed commitments. In total, approximately 82 percent of the Rights Issue is covered by subscription undertakings and guarantee commitments. Subscription undertakings have been submitted by a number of existing shareholders in the Company, including of the management and Board. Shareholders who have issued guarantee commitments have first entered a subscription undertaking corresponding to at least their share of the Rights Issue (pro-rata). For the guaranteed commitments, a guaranteed commission of twelve (12) percent of the guaranteed amount is paid in cash compensation or fifteen (15) if paid in new shares, corresponding to a total of approximately SEK  million. No compensation is paid for the subscription undertakings.
The Company will prepare an information memorandum for the Rights Issue, where the complete conditions and other information about the Rights Issue will be set out. The information memorandum is expected to be published on the Company's website, www.eeviahealth.com, on or around October 28, 2022, before the subscription period begins on November 1, 2022.
All dates occur within 2022. The schedule below for the Rights Issue is preliminary and may change.
- 25 October- Last trading day with shares including the right to receive subscription rights
- 26 October - First trading day with share without the right to receive subscription rights
- 27 October - Record date for participation in the Rights Issue. Shareholders who are registered in the shareholder register of the Company maintained by Euroclear Finland Oy or Euroclear Sweden AB on this day will receive subscription rights.
- 28 October - Estimated date for publication of the information memorandum
- 1 -10 November - Trading of subscription rights on the Spotlight Stock Market
- 1-15 November - Subscription period for the Rights Issue in Sweden
- 1-17 November - Subscription period for the Rights Issue in Finland
- 1 November until the shares subscribed in the Rights Issue are registered with the Finnish Trade Register- Trading with BTA's (paid subscribed shares)
- 22November - Estimated date for publication of the outcome from the Rights Issue
Partner Fondkommission is acting as the financial adviser and issuing agent in Sweden for the Rights Issue. OP Bank is the issuing agent in Finland.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Joel Westerström, Partner Fondkommission
Telephone: +358 400 22 5967 Telephone: +46 735 11 68 53
This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on October 20, 2022, at 14:00 CET.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
IMPORTANT INFORMATION ABOUT THE PRESS RELEASE AND DOCUMENTS
This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities only based on the information in the IM, which will be published before the start of the subscription period for the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden.
This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law. Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person, or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law. The IM, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence, or where this would contravene the law of that country.
No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered pursuant to the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilized, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.